• Fennec Pharmaceuticals highlighted PEDMARK, a sodium thiosulfate injection positioned as the only FDA-cleared therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients aged 1 month or older with localized, non-metastatic solid tumors.
• The presentation cited clinical data showing roughly a 50% reduction in hearing loss, framing PEDMARK as a way to preserve cisplatin use without compromising cancer treatment.
• Market protection was outlined with an expected U.S. generic entry no earlier than Sep. 1, 2033, alongside a 10-year Pediatric Use Marketing Authorization in Europe.
• International expansion plans included a European partnership with Norgine, Japan registration preparation, and a GCC partnership with InPharmus.
• Commercial execution updates included six consecutive quarters of revenue growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.